The FDA has approved duvelisib (Copiktra) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.
The company also noted that studies of duvelisib have shown that the most common all-grade adverse events (≥20% occurrence) in patients receiving the drug include diarrhea or colitis, neutropenia, rash, fatigue, pyrexia, cough, nausea, upper respiratory infection, pneumonia, musculoskeletal pain, and anemia.
Verastem Oncology Receives FDA Approval of COPIKTRA™ (duvelisib) Capsules. Published September 24, 2018. Accessed September 24, 2018. https://bit.ly/2NDQm80.
... to read the full story